Tashkent hosts regional regulators meeting with USP: the Center joins the PAR programme

On 29–30 September 2026 the Center for Pharmaceutical Products Safety, together with the US Pharmacopeia (USP) and the Agency for the Development of the Medical and Pharmaceutical Industry of the Republic of Uzbekistan, held two international events at BioPharm City, Tashkent.

Regional regulatory authorities meeting

The CAC Regulatory Authorities Meeting on 29 September brought together regulators from Uzbekistan, Kazakhstan, Kyrgyzstan, Tajikistan, Türkiye, Azerbaijan, Pakistan, Egypt, Jordan and Poland, as well as USP experts. Topics included:

• regional regulatory cooperation and reliance;
• pharmacopoeial standards, quality systems and regulatory assessment;
• regulatory approaches to bioequivalence, WHO prequalification and access to quality-assured medicines.

Letter of Agreement with USP

During the meeting a Letter of Agreement was signed on the Center joining USP's Preferential Access for Regulators (PAR) programme. Under the agreement:

• the Center and its laboratory network (central laboratory and regional branches) have their preferential access to USP Reference Standards used in quality control of medicines extended;
• the Center's specialists gain wider online access to the United States Pharmacopeia–National Formulary (USP–NF) and other USP official publications.

On the sidelines, the Center's Director Alisher Temirov held bilateral meetings with foreign regulators, international organisations and industry representatives on expanding cooperation, sharing best practice and building capacity.

USP User Forum

On 30 September the USP User Forum for specialists from pharmaceutical manufacturers and laboratories covered USP General Chapters, control of organic and elemental impurities and nitrosamines, USP Reference Standards, analytical method validation, stability of biotechnological medicinal products and management of laboratory nonconformities.

For reference: USP–NF is the United States Pharmacopeia and National Formulary, a compendium of quality standards for medicines. Reliance means a regulator taking decisions on the basis of assessments by another trusted regulator.

Sources: announcements by the Center for Pharmaceutical Products Safety and USP.